Horizon's Tepezza Broke The Mold For 2020 Launches, But Still Got Snared By COVID-19
An Interview With CEO Tim Walbert
Tepezza was the breakout launch of the year and will change Horizon's growth trajectory, but for now it has been sidelined by a supply constraint caused by COVID-19 vaccine manufacturing.
You may also be interested in...
Thyroid eye disease drug Tepezza is now expected to generate more than $1.55bn in full year sales, despite missing a full quarter of revenue.
Regeneron's COVID-19 antibody cocktail helped drive 38% growth for the company, while Global Blood Therapeutics' Oxbryta continues to face headwinds and Horizon focuses on relaunches.
US FDA approved new manufacturing for Tepezza, which had been sidelined by COVID-19 vaccine production. Horizon said it will resupply the market in April.